Steven Seedhouse
Stock Analyst at Raymond James
(3.67)
# 819
Out of 4,650 analysts
158
Total ratings
46.41%
Success rate
7.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Initiates: Strong Buy | $90 | $46.74 | +92.55% | 1 | Oct 24, 2024 | |
| KRRO Korro Bio | Initiates: Strong Buy | $153 | $63.85 | +139.62% | 1 | Oct 21, 2024 | |
| WVE Wave Life Sciences | Upgrades: Strong Buy | $13 → $22 | $14.99 | +46.76% | 2 | Oct 16, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $50 → $53 | $8.02 | +560.85% | 9 | Aug 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $116 → $118 | $74.52 | +58.35% | 17 | Jul 25, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $93 | $88.76 | +4.78% | 9 | Jul 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Strong Buy | $57 → $68 | $47.34 | +43.64% | 3 | May 10, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $34 → $51 | $28.12 | +81.37% | 2 | Apr 18, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $67 → $106 | $27.34 | +287.71% | 15 | Jan 11, 2024 | |
| ARDX Ardelyx | Maintains: Strong Buy | $12 → $15 | $5.90 | +154.24% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $30.78 | +81.94% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $39.54 | +61.86% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $4.15 | +321.69% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $16.34 | +248.84% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $3.31 | +20.85% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $21 → $19 | $1.57 | +1,110.19% | 13 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $4.61 | +377.22% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.26 | +421.47% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $17.49 | +100.11% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $49.08 | -22.58% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $45.72 | +55.29% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.92 | +445.26% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $30.49 | +24.63% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $19.57 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.90 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $185.01 | - | 2 | Apr 23, 2020 |
Q32 Bio
Oct 24, 2024
Initiates: Strong Buy
Price Target: $90
Current: $46.74
Upside: +92.55%
Korro Bio
Oct 21, 2024
Initiates: Strong Buy
Price Target: $153
Current: $63.85
Upside: +139.62%
Wave Life Sciences
Oct 16, 2024
Upgrades: Strong Buy
Price Target: $13 → $22
Current: $14.99
Upside: +46.76%
89bio
Aug 6, 2024
Maintains: Strong Buy
Price Target: $50 → $53
Current: $8.02
Upside: +560.85%
Viking Therapeutics
Jul 25, 2024
Maintains: Strong Buy
Price Target: $116 → $118
Current: $74.52
Upside: +58.35%
Gilead Sciences
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $88.76
Upside: +4.78%
Vera Therapeutics
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $47.34
Upside: +43.64%
Dianthus Therapeutics
Apr 18, 2024
Maintains: Outperform
Price Target: $34 → $51
Current: $28.12
Upside: +81.37%
Apellis Pharmaceuticals
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $27.34
Upside: +287.71%
Ardelyx
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.90
Upside: +154.24%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $30.78
Upside: +81.94%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $39.54
Upside: +61.86%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $4.15
Upside: +321.69%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $16.34
Upside: +248.84%
Nov 8, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $3.31
Upside: +20.85%
Nov 2, 2023
Maintains: Strong Buy
Price Target: $21 → $19
Current: $1.57
Upside: +1,110.19%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $4.61
Upside: +377.22%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.26
Upside: +421.47%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $17.49
Upside: +100.11%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $49.08
Upside: -22.58%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $45.72
Upside: +55.29%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.92
Upside: +445.26%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $30.49
Upside: +24.63%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $19.57
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.90
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $185.01
Upside: -